Sibutramine represents a new class of centrally acting pharmaceutical compounds referred to as serotoninnoradrenaline re-uptake inhibitors, or SNRIs. It is a tertiary amine and when deaminated to its major metabolites produces a dose dependent loss of weight. 1, 2 It is available for the treatment of obesity as Reductil 1 or as Meridia 1 in the United States.
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Sibutramine has been shown to increase satiety in humans. 3 In addition to reducing energy intake, however, sibutramine also increases energy expenditure in rodents 4 by activating central efferent sympathetic nerves innervating brown fat, thus mimicking the non-shivering thermogenic response to cold. This has raised the question whether stimulation of thermogenesis might play a role in weight loss in humans, particularly as there is evidence, including a small increase in pulse rate, that sibutramine activates the sympathetic nervous system in humans as well as in rodents.
The ®rst published study in humans on this question was by Seagle et al. 5 This study evaluated the response in resting metabolic rate (RMR) in 44 obese women instructed in the use of a 1200 kcal reducing diet and randomly assigned to receive a placebo, 10 or 30 mg of sibutramine daily for eight weeks, and again after discontinuing the agent for four additional weeks. The RMR was measured three hours following administration of the drug or placebo. Body weight and RMR declined in all groups, with the loss of weight in the sibutramine groups twice that of the placebo group at both time points. There was no difference in the decline in RMR amongst the groups whether adjusted or unadjusted for the decline in body size. Therefore, there was no evidence that sibutramine stimulated RMR three hours following acute dosing or that sibutramine blunted the inevitable decline in RMR associated with loss of weight.
The second paper to address this question yielded positive results. Hansen et al, 6 using a placebo-controlled randomized double-blind four-way crossover design, studied the fasting RMR and thermic effect of a 2.1 MJ meal in 11 non-obese men. Although metabolic rate was unaltered one hour following the administration of 30 mg sibutramine, this was followed by a signi®cant rise in both RMR and postprandial thermogenesis compared with placebo, particularly during the last 3.5 of the 5.5 hour measurement. Of interest, and in agreement with the pharmacological effects of the drug to increase sympathetic nervous system activity in rodents, 4 these changes were accompanied by increases in plasma adrenaline, heart rate and blood pressure. The treatment also enhanced signi®cantly the sensation of satiety in the postprandial period.
The literature to this point therefore suggests that sibutramine produces no acute or long-term stimulation of thermogenesis in obese women, but acutely increases RMR and the thermic effect of meals in lean men. This raises several questions. Sibutramine and its active metabolites reach their maximum concentrations after three hours, and their plasma half-lives are less than 24 hours. Could Seagle et al 5 have missed a thermogenic response when measuring the RMR at three hours (too early) and again at 24 hours (too late) following dosing? Clearly, no long term or chronic effect on thermogenesis was observed in this study. The question raised by the study of Hansen et al 6 concerns whether lean men and obese women respond differently to sibutramine? Two new contributions to the debate now appear in the present issue of the Journal, and although they add additional light, doubts about these questions remain and others are raised.
In a chronic study carried out by Hansen et al, 7 indirect calorimetry was carried out in a respiration chamber to measure changes in total daily energy expenditure and its components. Thirty-two (7 male and 25 female) obese subjects received 15 mg sibutramine daily in an eight week placebo controlled double-blind manner without dietary intervention. This treatment with sibutramine alone produced a greater loss of weight than placebo, but there was a very similar decline in 24-hour energy expenditure over the eight weeks in both groups. Thus, when adjusted for changes in body weight (but not for fatfree mass), sibutramine was found to have blunted signi®cantly the decline in 24-hour energy expenditure. There was no apparent change in ®dgeting or physical activity between the groups in the chamber. Once again, satiety was increased by sibutramine.
In the other paper, by Walsh et al, 8 19 obese females were instructed to consume a diet calculated to produce a 600 kcal daily de®cit for 12 weeks and, in a double-blind fashion, received 15 mg sibutramine or placebo daily. Fasting RMR was estimated before starting the diet, and again after 12 weeks of dieting. Weight was lost, but this was not statistically different between the two groups, and although adjusting RMR for weight loss suggested that sibutramine appeared to blunt the decline in RMR, this was not statistically signi®cant. These workers also failed to detect any increase in the thermogenic response to an infusion of adrenaline after chronic treatment with sibutramine.
These two new contributions con®rm the wellknown observation that energy expenditure declines as body weight is shed. Also, both show that sibutramine does not stimulate thermogenesis above normal in obese humans. However, although both claim that sibutramine blunted the decline in energy expenditure accompanying the weight loss, only in the drug-alone study of Hansen et al 6 is this clearly signi®cant. As with the trial by Seagle et al, 5 one wonders if Walsh and co-workers 7 had missed any thermogenic effect by measuring fasting RMR 24 hours after the last dose of sibutramine. Thus, the evidence that sibutramine stimulates thermogenesis in obese humans is inconclusive, and whatever effect there might be, it is certainly less than that seen in rodents, where it increases thermogenesis above normal and even raises body temperature. 4 Nevertheless, it has to be remembered that it only takes very small mismatches between energy expenditure and energy intake to produce large changes in weight over time.
The most unequivocal study is the one in lean subjects 6 where the thermic effect of a meal was clearly exaggerated by sibutramine, and weight loss was not an issue. However, determining with con®-dence whether sibutramine blunts the decline in energy expenditure during or following weight loss is a much more dif®cult task, particularly when the changes are small. Any small increase in thermogenesis can be easily masked by the decline in energy expenditure that follows weight loss. This is emphasized by the statistically different result when change in body weight and body composition were covaried with energy expenditure in the Hansen study. 7 It is also likely, given the number of subjects, the variance in the measurements and the magnitude of responses, that the present studies had insuf®cient statistical power to determine signi®cant changes with a high degree of con®dence. This is unfortunate, since small effects (even smaller than those seen so far) could be clinically signi®cant in the long-term treatment of the obese.
In spite of these reservations, it is encouraging that there is some evidence to show that anti-obesity drugs like sibutramine might help enhance weight loss by stimulating thermogenesis and blunting the usual, frustrating decline in energy expenditure that accompanies dieting. Since the expected effects are now known to be quite small, future studies need to have suf®cient statistical power to pick-up these small differences. Future studies should also consider carefully the pharmacokinetics of sibutramine and its metabolites, the timing of drug administration with respect to the next and subsequent meals, and whether to study in the fed and fasted state. Since the effects of weight loss and restricted caloric intake have their own effects on energy expenditure, future studies should be considered that exclude or control for these confounders, rather than relying on post hoc covariant adjustments. Finally, it is possible that the sympathomimetic effects of sibutramine following longer treatment could improve its capacity to stimulate thermogenesis by increasing the growth and differentiation of brown fat, as seen in rodents.
In conclusion, the literature suggests that sibutramine is capable of augmenting thermogenesis in humans, particularly in the lean. The magnitude of this response in the obese seems quite small, and although this has potential clinical signi®cance, it is less important to the loss of weight than its effects to restrain caloric intake by increasing satiety.
